Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**RNU6-276P** refers to a pseudogene member of the U6 small nuclear RNA family. U6 small nuclear RNAs (snRNAs) are critical non-coding RNA components of the spliceosome complex, which catalyzes the removal of introns from pre-mRNA—a key step in mRNA maturation in eukaryotes[1][2]. However, RNU6-276P is a pseudogene: it is a non-functional, typically non-expressed genomic sequence derived from the U6 snRNA gene, likely generated via retrotranspositional processes[3]. While the canonical U6 snRNA gene (for example, RNU6-1 in humans) is crucial for splicing, pseudogenes like RNU6-276P do not produce a functional RNA product and have no known role in splicing or other biological functions[1][2][3]. Pseudogenes are generally not considered therapeutic targets, do not interact with drugs or function as disease-relevant biomarkers, and have no established involvement in disease pathogenesis or patient safety[2][3]. **Additional context:** - **U6 small nuclear RNA** is highly conserved and essential for spliceosome function[1][2]. - **Pseudogenes** like RNU6-276P are frequent in the genome due to the evolutionary importance and high copy number of U6 snRNA genes in vertebrates[2][3]. **Key limitation:** The sequence RNU6-276P specifically specifies a pseudogene—a non-functional remnant of a U6 snRNA gene, not a receptor, enzyme, or therapeutic target. If you intend to refer to functional U6 snRNA, use "U6 small nuclear RNA" or "RNU6" (without pseudogene designation)[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on U6 small nuclear RNA 276, pseudogene (RNU6-276P).